CD4 and pulmonary tuberculosis: The strong protective efficacy demonstrated by CysVac2 in multiple models of M. tuberculosis challenge, coupled with the induction of defined subsets of lung multifunctional CD4+ T cell that correlate with protection, warrants further appraisal of the vaccine candidate for the control of pulmonary TB in humans.